Accessibility Menu
Lifecore Biomedical logo

Lifecore Biomedical(NASDAQ) LFCR

Market Cap$181.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-65%
5 Year-55%
1 Year-37%
1 Month-0%
$4.77
+7.43%
+0.33Today
After hours$4.87+$0.10 (+2.10%)
Lifecore Biomedical last closing stock price
MetricPriceDate
Last closeUSD 4.842026-08-06
Lifecore Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.01%USD 4.362026-07-30
1 month-0.41%USD 4.862026-07-07
3 month+1.04%USD 4.792026-05-08
Year to date-40.83%USD 8.182025-12-31
1 year-37.39%USD 7.732025-08-06
3 year-54.81%USD 10.712023-08-07
5 year-55.02%USD 10.762021-08-06
Since inception-65.18%USD 12.751996-02-15

Lifecore Biomedical Financials at a Glance

Market Cap

$181.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$119.22M

Net Income (TTM)

-$28.98M

EPS (TTM)

-$1.30

P/E Ratio

-3.71

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$4.77

Volume

246,714.459

Open

$4.49

Previous Close

$4.84

Daily Range

$4.46 - $4.92

52-Week Range

$3.63 - $8.98

Estimated Earnings Date

Oct 2, 2026

LFCR: Motley Fool Moneyball Superscore

47

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lifecore Biomedical

Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) that specializes in the creation and production of sterile injectable pharmaceutical products. Known for its expertise in using hyaluronic acid (HA), the company serves a wide range of medical needs. Leveraging over 40 years in the industry, Lifecore partners with both emerging and established biopharmaceutical companies to deliver high-quality, regulatory-compliant products.

Products and Services

Development and manufacturing of sterile injectable products in syringes, vials, and cartridges.

Production of injectable-grade sodium hyaluronic acid in bulk and finished forms.

Contract manufacturing services focusing on aseptic filling and complex formulation delivery.

Product development services, including material changes and clinical study material production.

What Makes Lifecore Biomedical, Inc. Special

Lifecore's distinctiveness resides in its focus on hyaluronic acid-based products and sterile injectable manufacturing. Its comprehensive services, from development through to final production, offer partners flexibility and efficiency. Strong relationships with biopharmaceutical companies and a proven regulatory track record further enhance its reputation as a reliable CDMO partner.

Five Things You Need to Know

Lifecore uses bacterial fermentation to produce high-quality hyaluronic acid.

Its core strength lies in delivering sterile injectable solutions across various medical applications.

The company has made significant investments to expand its aseptic filling capabilities.

Lifecore maintains a single, integrated business segment focused on CDMO services.

Lifecore's operations are centrally located in Chaska, Minnesota, USA.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Employees

382

CEO

Paul Josephs

Headquarters

Chaska, MN 55318, US

LFCR Financials

Key Financial Metrics (TTM)

Gross Margin

30.86%

Operating Margin

-0.86%

Net Income Margin

-24.30%

Return on Equity

-194.95%

Return on Capital

-0.98%

Return on Assets

-12.63%

Earnings Yield

-26.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$181.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.51M

Volume

246.71K

Avg. Volume

197.16K

Financials (TTM)

Gross Profit

$36.79M

Operating Income

-$1.02M

EBITDA

$13.28M

Operating Cash Flow

$4.81M

Capital Expenditure

-$4.89M

Free Cash Flow

-$81.29K

Cash & ST Invst.

$17.24M

Total Debt

$155.07M

Lifecore Biomedical Performance Analysis

Lifecore Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-05-31USD 111,270,000N/A
20232023-05-31USD 103,269,000-7.2%
20242024-05-31USD 128,261,00024.2%
20252025-05-31USD 128,867,0000.5%
Lifecore Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-14.6%
Q42025-12-3132.6%
Q32026-03-31-32.1%
Q22026-06-309.8%
Lifecore Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-05-31USD -3.97N/A
20232023-05-31USD -3.32-16.3%
20242024-05-31USD 0.33N/A
20252025-05-31USD -1.27N/A
Lifecore Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-424.4%
Q42025-12-31109.3%
Q32026-03-31-126.3%
Q22026-06-3034.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$30.75M

-15.6%

Gross Profit

$12.46M

-10.9%

Gross Margin

40.52%

N/A

Market Cap

$181.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$447.16K

N/A

Employees

406

N/A

Net Income

$2.15M

+287.5%

EBITDA

$15.59M

+146.6%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$17.24M

+108.6%

Total Debt

$155.07M

+18.5%

Accounts Receivable

$30.46M

-30.3%

Inventory

$25.48M

-21.1%

Long Term Debt

$154.10M

+21.3%

Short Term Debt

$970.00K

-74.6%

Return on Assets

-12.63%

N/A

Return on Invested Capital

-0.49%

N/A

Free Cash Flow

-$2.70M

-183.1%

Operating Cash Flow

-$2.19M

-140.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACBAurora Cannabis Inc.
$2.98+2.41%
PRQRProQR Therapeutics N.V.
$1.90-3.55%
CVRXCVRx, Inc.
$5.94+6.45%
OMIOwens & Minor, Inc.
$2.68+8.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%
SPCXSpace Exploration Technologies
$114.92+0.06%

Questions About LFCR

What is the current price of Lifecore Biomedical?

Lifecore Biomedical is trading at $4.84 per share.

What is the 52-week range for Lifecore Biomedical?

Over the past 52 weeks, Lifecore Biomedical has traded between $3.63 and $8.98.

How much debt does Lifecore Biomedical have?

As of the most recent reporting period, Lifecore Biomedical reported total debt of $156.38M.

How much cash does Lifecore Biomedical have on hand?

Lifecore Biomedical reported $17.24M in cash and cash equivalents in its most recent financial results.

What is Lifecore Biomedical’s dividend yield?

Lifecore Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.